Difference between revisions of "P63"
Jump to navigation
Jump to search
(re-order) |
|||
| Line 1: | Line 1: | ||
{{ Infobox immunostain | |||
| Name = {{PAGENAME}} | |||
| Image = High_grade_squamous_intraepithelial_lesion_-_2_-_p63_--_intermed_mag.jpg | |||
| Width = | |||
| Caption = p63 staining in squamous epithelium with dysplasia. | |||
| Abbrev = | |||
| Synonyms = | |||
| Similar = p40 (more specific for squamous cell carcinoma) | |||
| Clones = | |||
| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous) | |||
| Subspecial = | |||
| Pattern = nuclear staining | |||
| Positive = [[squamous cell carcinoma]], [[urothelial carcinoma]] | |||
| Negative = [[prostate carcinoma]], most [[lung adenocarcinoma]], breast carcinoma | |||
| Other = | |||
}} | |||
'''p63''' is a commonly used [[immunostain]]. p63, like most other "p" stains, is a nuclear stain. | '''p63''' is a commonly used [[immunostain]]. p63, like most other "p" stains, is a nuclear stain. | ||
Revision as of 02:16, 23 September 2015
| P63 | |
|---|---|
| Immunostain in short | |
 p63 staining in squamous epithelium with dysplasia. | |
| Similar stains | p40 (more specific for squamous cell carcinoma) |
| Use | breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous) |
| Normal staining pattern | nuclear staining |
| Positive | squamous cell carcinoma, urothelial carcinoma |
| Negative | prostate carcinoma, most lung adenocarcinoma, breast carcinoma |
p63 is a commonly used immunostain. p63, like most other "p" stains, is a nuclear stain.
Pattern
- Nuclear staining.
Note:
- Cytoplasmic staining suggestive of muscle differentiation - seen in rhabdomyosarcoma.[1]
Classic use
Subtype marker:
- Marker of squamous cell carcinoma.
- Urothelial carcinoma.[2]
Thresholding (invasive vs. pre-invasive):
- Prostate basal cell marker.
- Breast myoepithelial cell marker.
Non-classic tumours
- Di Como et al[3] looked at a large cross-section of tumours.
- Jo and Fletcher[4] did a paper on soft tissue lesions and p63.
See also
References
- ↑ Martin, SE.; Temm, CJ.; Goheen, MP.; Ulbright, TM.; Hattab, EM. (Oct 2011). "Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.". Mod Pathol 24 (10): 1320-6. doi:10.1038/modpathol.2011.89. PMID 21623385.
- ↑ Lewis, JS.; Ritter, JH.; El-Mofty, S. (Nov 2005). "Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1.". Mod Pathol 18 (11): 1471-81. doi:10.1038/modpathol.3800451. PMID 15976812.
- ↑ Di Como, CJ.; Urist, MJ.; Babayan, I.; Drobnjak, M.; Hedvat, CV.; Teruya-Feldstein, J.; Pohar, K.; Hoos, A. et al. (Feb 2002). "p63 expression profiles in human normal and tumor tissues.". Clin Cancer Res 8 (2): 494-501. PMID 11839669.
- ↑ Jo, VY.; Fletcher, CD. (Nov 2011). "p63 immunohistochemical staining is limited in soft tissue tumors.". Am J Clin Pathol 136 (5): 762-6. doi:10.1309/AJCPXNUC7JZSKWEU. PMID 22031315.